Cytokine Release Syndrome: Inhibition of Pro-Inflammatory Cytokines As a Solution for Reducing Covid-19 Mortality Publisher Pubmed



Moradian N^{1, 2} ; Gouravani M^{1, 2} ; Salehi MA^{1, 2} ; Heidari A^{1, 2} ; Shafeghat M^{1, 2} ; Hamblin MR^{3, 4, 5} ; Rezaei N^{1, 2, 6}
Source: European Cytokine Network Published:2020

Abstract

Coronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patients in comparison with mildly affected patients suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha, and their mechanism of action in the CRS cascade is explained. Potential therapeutic approaches involving anti-IL-6 and anti-TNF-alpha antibodies to fight COVID-19 and reduce mortality rate in severe cases are also discussed. © 2020, JLE/Springer.